Long Term Evaluation of the Effect of Botulinum Toxin A Injection on the Masseteric

교근 비대 환자에서 보툴리눔 A형 독소 주사 효과의 장기적 평가

  • Hong, Hee-Suk (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kang, Seung-Chul (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kim, Chong-Youl (Dept. of Oral Medicine, College of Dentistry, Yonsei University) ;
  • Kim, Seong-Taek (Dept. of Oral Medicine, College of Dentistry, Yonsei University)
  • 홍희숙 (연세대학교 치과대학 구강내과학교실) ;
  • 강승철 (연세대학교 치과대학 구강내과학교실) ;
  • 김종열 (연세대학교 치과대학 구강내과학교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Published : 2005.03.30


In this experiment, eleven volunteers were followed up for 15 months after the injection of botulinum toxin type A on right and left masseter muscles. The measurement of masseter muscle atrophy for each volunteer was performed by CT(computed tomography) three times: before the injection, three and fifteen months after the injection. The thickness and area of muscle were measured in three positions which are 10 (position 1), 20 (position 2), and 40 mm (position 3) above the inferior border of mandible(the injection site was nearest the position 1). The thickness of masster muscle was decreased in all three positions three months after the injection, but no significant change was observed fifteen months after the injection. On the other hand, the area of masster muscle was decreased in all three positions three months after the injection. Furthermore, the area was decreased significantly in positions 1 and 2, but not in position 3 fifteen months after the injection. As a result, toxin is still in effect even fifteen months after the injection. Finally, the present study shows that the measurement of muscle area provides more precise informations than that of muscle thickness does.


  1. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40(2):277-280 https://doi.org/10.1212/WNL.40.2.277
  2. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 1994;32(1):26-28 https://doi.org/10.1016/0266-4356(94)90168-6
  3. Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorder: preliminary findings. J Oral Maxillofac Surg 1999;57(8):916-920 https://doi.org/10.1016/S0278-2391(99)90007-1
  4. Gurney CE. Chronic bilateral benign hypertrophy of the masseter muscles. Am J Surg 1947;73:137-139 https://doi.org/10.1016/0002-9610(47)90304-8
  5. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomograpic management. Dermatol Surg 2003;29(5):484-489 https://doi.org/10.1046/j.1524-4725.2003.29117.x
  6. 장희영. 전산화 단층촬영으로 평가한 교근에 대한 보툴리눔 A 형 독소주사와 교합안정장치의 효과. 연세대학교 치의학과 박사논문, 2004
  7. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;9(1):31-39 https://doi.org/10.1002/mds.870090106
  8. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol soc 1981;79:734-770
  9. von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001;107:327-332 https://doi.org/10.1097/00006534-200102000-00004
  10. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001;54:197-200 https://doi.org/10.1054/bjps.2000.3526
  11. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof TC, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994;269(3):1617-1620
  12. Smyth AG. Botulinum toxin treatment of bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg 1994;32(1):29-33 https://doi.org/10.1016/0266-4356(94)90169-4
  13. Ivanhoe CB, Lai JM, Francisco GE. Bruxim after brain injury: Successful treatment with botulinum toxin-A. Arch Phys Med Rehabil 1997;78:1272-1273 https://doi.org/10.1016/S0003-9993(97)90343-9
  14. Niamtu J 3rd. Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg 1999;57(10):1228-1233 https://doi.org/10.1016/S0278-2391(99)90493-7
  15. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migrane preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40(6):445-450 https://doi.org/10.1046/j.1526-4610.2000.00066.x
  16. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003;29(5):477-483 https://doi.org/10.1046/j.1524-4725.2003.29116.x
  17. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002;27(11): 552-558 https://doi.org/10.1016/S0968-0004(02)02177-1
  18. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A(BOTOX) for treatment of migraine headaches; an open-label study. Otolaryngol Head Neck Surg 2000;123(6):669-676 https://doi.org/10.1067/mhn.2000.110960
  19. Pidcock FS, Wise JM, Christensen JR. Treatment of severe post-traumatic bruxism with botulinum toxin-A: Case report. J Oral Maxillofac Surg 2002;60:115-117 https://doi.org/10.1053/joms.2002.29127
  20. Legg JW. Enlargement of the temporal and masseter muscles on both sides. Trans Pathol Soc Lond 1880;31:361